Andere Sprachen Biomm S.A.

Aktien

A0YKDH

BRBIOMACNOR2

BIOM3

Verzögert Sao Paulo Andere Börsenplätze 16:36:31 17.05.2024			% 5 Tage	% 1. Jan.
15,97 ^BRL	-2,38 %		-11,28 %	+176,30 %

17.04.	Biocon Limited unterzeichnet einen exklusiven Lizenz- und Liefervertrag mit Biomm S.A.	CI
27.03.	Biomm S.A. meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil	18.04.
Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A	17.04.
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Biomm S A : Webcast Presentation 3Q23	14.11.
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11.08.23
Biomm S A : Apresentação de resultados 2T23	10.08.23
Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, A Stelara Biosimilar	16.06.23
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	11.05.23
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23.03.23
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23.03.23
Biomm S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11.11.22
Biomm S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12.08.22
Biomm S A : Presentation of 1Q22 Results	16.05.22
Biomm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	14.05.22
Biomm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	25.03.22
Biomm S A : Comunicado ao Mercado	03.03.22
Lupin Enters Partnership to Market Biosimilar Pegfilgrastim in Brazil	06.12.21
CytoDyn : Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)	23.09.21
Biomm S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13.08.21

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Biomm S.A.

Aktien

A0YKDH

BRBIOMACNOR2

BIOM3

Andere Sprachen

Filter